IAAG
BMRN icon

Innovative Asset Advisors Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Innovative Asset Advisors Group’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-102
Closed -$5.76K – 368
2026
Q1 		$5.76K Buy
+102
New +$5.95K ﹤0.01% 748

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Innovative Asset Advisors Group's BMRN Position: Q2 2026 in Review

Innovative Asset Advisors Group sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2026, closing a stake of 102 shares — an estimated $5.76K sold.

Innovative Asset Advisors Group first reported a position in BMRN in Q1 2026 and held it in 1 quarter. The position peaked at $5.76K in Q1 2026. 526 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Innovative Asset Advisors Group reported no remaining BioMarin Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Innovative Asset Advisors Group sold 102 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $5.76K.
  • Innovative Asset Advisors Group first reported a position in BioMarin Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Innovative Asset Advisors Group's BioMarin Pharmaceuticals position peaked at $5.76K in Q1 2026.
  • 526 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Innovative Asset Advisors Group's 13F filing for Q2 2026, filed 5 Aug 2026.